Bone Therapeutics (0R55) Ratios
Bone Therapeutics Ratios
GB:0R55's free cash flow for Q4 2025 was $0.00. For the 2025 fiscal year, GB:0R55's free cash flow was increased by $1.18M and operating cash flow was $-1.18M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Jun 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.55 | 0.21 | 0.12 | 0.45 | 0.75 |
| Quick Ratio | 0.55 | 0.21 | 0.12 | 0.45 | -0.73 |
| Cash Ratio | 0.01 | 0.05 | 0.01 | 0.18 | 6.37 |
| Solvency Ratio | 3.90 | -0.14 | -0.88 | -0.08 | -0.04 |
| Operating Cash Flow Ratio | -0.20 | -0.28 | -0.22 | -0.18 | -8.56 |
| Short-Term Operating Cash Flow Coverage | -0.28 | -0.50 | -0.29 | -0.25 | -10.21 |
| Net Current Asset Value | $ -2.45M | $ -29.92M | $ -30.42M | $ -21.57M | $ -25.41M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.11 | 5.85 | 2.98 | 0.81 | 0.18 |
| Debt-to-Equity Ratio | -1.95 | -1.11 | -1.24 | 6.75 | -1.32 |
| Debt-to-Capital Ratio | 2.06 | 10.45 | 5.09 | 0.87 | 4.12 |
| Long-Term Debt-to-Capital Ratio | -0.01 | -12.62 | -2.12 | 0.81 | -5.73 |
| Financial Leverage Ratio | -1.75 | -0.19 | -0.42 | 8.32 | -7.41 |
| Debt Service Coverage Ratio | -0.35 | -0.78 | -0.38 | -0.28 | -0.70 |
| Interest Coverage Ratio | -189.00 | -4.93 | -1.18 | -8.34 | -11.11 |
| Debt to Market Cap | 2.53 | 20.66 | 3.27 | 1.96 | 0.25 |
| Interest Debt Per Share | 0.01 | 0.13 | 0.25 | 0.20 | 0.17 |
| Net Debt to EBITDA | -2.82 | -5.65 | -4.18 | -9.72 | 6.93 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 100.00% | 316.35% |
| EBIT Margin | 0.00% | 0.00% | -1296.32% | -783.11% | -281.09% |
| EBITDA Margin | 0.00% | 0.00% | -1251.57% | -762.84% | -276.92% |
| Operating Profit Margin | 0.00% | 0.00% | -1296.50% | -783.11% | -381.09% |
| Pretax Profit Margin | 0.00% | 0.00% | -5345.86% | -1030.07% | -315.38% |
| Net Profit Margin | 0.00% | 0.00% | -5299.82% | -689.53% | -315.38% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -5344.57% | -1030.07% | -315.38% |
| Net Income Per EBT | 100.00% | 71.07% | 99.14% | 66.94% | 100.00% |
| EBT Per EBIT | -1582.24% | 81.10% | 412.33% | 131.54% | 82.76% |
| Return on Assets (ROA) | 612.79% | -100.55% | -301.06% | -6.96% | -4.98% |
| Return on Equity (ROE) | -1070.19% | 19.02% | 125.60% | -57.88% | 36.85% |
| Return on Capital Employed (ROCE) | 68.58% | 257.45% | 112.01% | -12.22% | -6.51% |
| Return on Invested Capital (ROIC) | -71.55% | -645.75% | -119.41% | -8.59% | -18.68% |
| Return on Tangible Assets | 612.79% | -100.61% | -438.02% | -19.95% | -4.98% |
| Earnings Yield | 1394.06% | -355.36% | -343.14% | -17.70% | -6.93% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 1.63 | 0.12 | 0.12 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.03 | 0.14 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.78 | 0.21 | 0.36 |
| Asset Turnover | 0.00 | 0.00 | 0.06 | 0.01 | 0.02 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | -0.06 | -0.10 | 0.07 |
| Cash Conversion Cycle | 0.00 | 0.00 | 224.51 | -9035.39 | 62739.05 |
| Days of Sales Outstanding | 0.00 | 0.00 | 224.51 | 3070.44 | 3019.44 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 62302.69 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 12105.83 | 2583.08 |
| Operating Cycle | 0.00 | 0.00 | 224.51 | 3070.44 | 65322.13 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.01 | -0.03 | -0.02 | -0.60 |
| Free Cash Flow Per Share | 0.00 | 0.00 | -0.03 | -0.02 | -0.61 |
| Dividend Paid and CapEx Coverage Ratio | -1.00 | -1.00 | -0.99 | -382.00 | -61.76 |
| Capital Expenditure Coverage Ratio | -1.00 | -1.00 | -0.99 | -382.00 | -61.76 |
| Operating Cash Flow Coverage Ratio | -0.28 | -0.08 | -0.12 | -0.08 | -3.63 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -6.39 | -6.45 | -40.97 |
| Free Cash Flow Yield | 0.00% | 0.00% | -41.37% | -16.60% | -91.53% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 0.07 | -0.28 | -0.29 | -5.65 | -14.42 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 15.45 | 38.96 | 45.49 |
| Price-to-Book (P/B) Ratio | -0.77 | -0.05 | -0.37 | 3.27 | -5.32 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.00 | 0.00 | -2.42 | -6.02 | -1.09 |
| Price-to-Operating Cash Flow Ratio | -1.43 | -0.60 | -2.42 | -6.04 | -1.11 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.00 | -0.00 | 0.09 | 0.15 |
| Enterprise Value Multiple | -3.96 | -5.93 | -5.41 | -14.83 | -9.50 |
| Enterprise Value | 5.24M | 28.68M | 36.79M | 33.48M | 8.21M |
| EV to EBITDA | -3.96 | -5.93 | -5.41 | -14.83 | -9.50 |
| EV to Sales | 0.00 | 0.00 | 67.75 | 113.10 | 26.31 |
| EV to Free Cash Flow | 0.00 | 0.00 | -10.60 | -17.48 | -0.63 |
| EV to Operating Cash Flow | -4.98 | -12.84 | -10.60 | -17.53 | -0.64 |
| Tangible Book Value Per Share | -0.00 | -0.12 | -0.19 | -0.13 | -0.32 |
| Shareholders’ Equity Per Share | -0.00 | -0.11 | -0.17 | 0.03 | -0.13 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | -0.09 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net Income Per Share | 0.03 | -0.02 | -0.21 | -0.02 | -0.05 |
| Tax Burden | 1.00 | 0.71 | 0.99 | 0.67 | 1.00 |
| Interest Burden | -15.82 | 1.33 | 4.12 | 1.32 | 1.12 |
| Research & Development to Revenue | 0.00 | 0.00 | 6.89 | 3.48 | 1.98 |
| SG&A to Revenue | 0.00 | 0.00 | 6.72 | 2.09 | 5.67 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -0.32 |
| Income Quality | -0.05 | 0.47 | 0.12 | 0.82 | 1.06 |
Currency in EUR